Lawsuit Alleges Securities Fraud by Unicycive Therapeutics

Glancy Prongay Wolke & Rotter LLP announced on September 25, 2026, that investors who sustained losses in Unicycive Therapeutics, Inc. have an opportunity to lead a securities fraud class action lawsuit against the company.

The complaint alleges that between December 29, 2025, and June 29, 2026, defendants made materially false or misleading statements and failed to disclose adverse material facts about the company's business, operations, and prospects. These allegations stem from the company's alleged failure to properly oversee its third-party manufacturing vendor.

Specifically, the lawsuit claims Unicycive Therapeutics did not inspect its vendor's facility or audit its compliance with current good manufacturing practices. As a result, the company allegedly lacked a reasonable basis to believe the vendor had resolved deficiencies cited by the U.S. Food and Drug Administration (FDA).

This oversight allegedly created an undisclosed risk that the FDA would require additional information on the vendor's manufacturing practices, potentially delaying the regulatory approval of the company's drug, OLC. The lawsuit contends that defendants' positive statements about the company's business were therefore misleading.

Investors who wish to serve as lead plaintiff must file relevant documents with the court by November 2, 2026. Glancy Prongay Wolke & Rotter LLP is encouraging affected investors to contact the firm to learn more about their rights and potential claims.